Canada: January 2017 Deal Round-Up

Last Updated: February 13 2017
Article by Cameron Mingay

The following is a summary of major deals in the life science space that closed or were announced as closed in January 2017. Vancouver-based Quark Venture Inc., through its Global Health Sciences Venture Fund, continued to be an active investor, with investments made both in Canada and the United States in the month of January 2017.


Date: Closed January 3, 2017

Type: Amalgamation

Companies: Avagenesis Corp (TSXV: VVA) and Avapecia Life Sciences Corp. (CSE: VVS)

Deal size: Approx. CDN $12.13 million

Description: On January 3, 2017, Avapecia Life Sciences Corp. ("Avapecia") and Avagenesis Corp. ("Avagenesis") announced the completion of the transactions contemplated in their amalgamation agreement dated November 10, 2016. The amalgamated company, Liberty Biopharma Inc. ("Liberty"), will continue the business of both Avagenesis and Avapecia. Its common shares were listed on the TSX Venture Exchange under the symbol "LTY" on January 6, 2017. Avagenesis shareholders were issued one post-amalgamation Liberty common share in exchange for each Avagenesis common share held, for a total issuance of 56,014,909 shares. Avapecia shareholders were issued one post-amalgamation Liberty common share in exchange for every three Avapecia common shares held, for a total issuance of 48,500,300 shares. The amalgamated corporation, Liberty, is a biotechnology company engaged in the research, development and commercialization of regenerative stem cell technologies and therapy solutions for use in urogynaecology, urology, hair loss and a number of other diseases.

Source: Avagenesis Corp. and Avapecia Life Sciences Corp., Press Release, "Avagenesis and Avapecia Complete Merger and Continue as Liberty Biopharma Inc." (January 3, 2017)

Date: January 10, 2017

Type: Acquisition

Target: 2344823 Ontario Inc. d/b/a Bodystream

Acquirer: Mettrum Health Corp.

Deal size: CDN $1 million in cash and 451,596 Mettrum shares, as well as additional shares to a maximum of 1,505,322 Mettrum shares over the next three to five years, subject to Bodystream achieving certain operational milestones.

Description: On January 10, 2017, Mettrum Health Corp. ("Mettrum") acquired all of the outstanding shares of 2344823 Ontario Inc. d/b/a Bodystream. Under the terms of the transaction, Mettrum paid $1 million in cash and issued 451,596 Mettrum shares from treasury to shareholders of Bodystream. Mettrum will also issue up to a maximum of 1,505,322 additional shares over the next three to five years subject to Bodystream achieving certain operational milestones. Bodystream operates a network of medical cannabis clinics across Ontario.

Source: Mettrum Health Corp., Press Release, "Mettrum Health Corp. to Acquire Bodystream Cannabis Clinic Network" (January 10, 2017)

Date: January 31, 2017

Type: Acquisition

Target: Mettrum Health Corp. (TSXV: MT)

Acquirer: Canopy Growth Corporation (TSX: CGC)

Description: On January 31, 2017, Canopy Growth Corporation ("Canopy Growth") and Mettrum Health Corp. ("Mettrum") completed the closing of the acquisition of Mettrum by Canopy Growth (see here for details). Mettrum shareholders received 0.7132 common shares of Canopy Growth for each Mettrum share held immediately prior to closing.

Source: Press Release, "Canopy Growth and Mettrum Announce Closing of Acquisition" (January 31, 2017)


Date: Announced as closed January 5, 2017

Type: Private Placement

Issuer: Microbion Corporation

Investor(s): Quark Venture Inc. and GF Securities, through the Global Health Sciences Venture Fund

Deal size: US $25 million (approx. CDN $33 million)

Description: On January 5, 2017, Vancouver-based Quark Venture Inc. ("Quark") and GF Securities announced a US $25 million investment in Microbion Corporation ("Microbion") through the Global Health Sciences Venture Fund. Microbion, located in Vancouver and Bozeman, MT, is a clinical stage biopharmaceutical company specializing in the treatment of antibiotic resistant infections. It is currently developing a treatment for diabetic foot ulcer infections.

Source: Quark Venture Inc. & Microbion Corporation,  Press Release, "Quark Venture and GF Securities Invest US$25 Million in Microbion to Advance a New Class of Drugs that Combat Antibiotic-Resistant Infections", (January 5, 2017).

Date: January 10, 2017

Type: Non-brokered private placement

Issuer: Veritas Pharma Inc. (CSE: VRT)

Investor(s): Marapharm Ventures Inc.

Deal size: Total gross proceeds of CDN $2,181,650

Description: On January 10, 2017, Veritas Pharma Inc. ("Veritas") announced that it had completed a non-brokered private placement of 9,916,590 units ("Units") at a price of $0.22 per Unit for aggregate gross proceeds of $2,181,650 (the "Offering"). Each Unit is comprised of one common share ("Share") and one Share purchase warrant of Veritas ("Warrant").  Each Warrant entitles the holder to purchase one Share (a "Warrant Share") at an exercise price of $0.30 per Warrant Share for a period of 18 months from the date of issuance, subject to an acceleration clause. Marapharm Ventures Inc. ("Marapharm") announced that it had subscribed for a total of 5 million units in the Offering for a total investment of $1,100,000.00. Veritas is a discovery and development company developing cannabis strains for disease specific actions such as chronic pain, nausea and vomiting, muscle spasms, epilepsy and PTSD. Marapharm is a developmental stage medical marijuana company with operations based in British Columbia.

Source: Veritas Pharma Inc., Press Release, "Private Placement Offering" (January 10, 2017); Marapharm Ventures Inc., Press Release, "Marapharm Ventures Inc. invests in Veritas Pharma Inc." (January 9, 2017).

Date: Announced January 27, 2017

Type: Series B private placement financing

Issuer: Biscayne Neurotherapeutics, Inc. (a clinical stage company established by Biscayne Pharmaceuticals)

Investor(s): Quark Venture Inc. and GF Securities (through the Global Health Sciences Fund), Mesa Verde Venture Partners, as well as current shareholders

Deal size: US $3 million (Approx CDN $3.9 million)

Description: On January 27, 2017, Biscayne Neurotherapeutics, Inc. ("Biscayne") announced the completion of a US $3 million Series B financing led by the Global Health Sciences Fund of Quark Venture Inc. and GF Securities, Mesa Verde Venture Partners, and other private investors. Biscayne is a clinical stage company, developing an antiepileptic compound for treatment adults with refractory complex partial seizures.

Source: Biscayne Neurotherapeutics Inc., Press Release, "Biscayne Announced Formation of Biscayne Neurotherapeutics and Completion of Series B Financing" (January 27, 2017)

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions